Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist

Abstract

This study confirmed both the efficacy and the safety of IL-1Ra in a large cohort of patients with active and severe RA. IL-1Ra is the first biologic agent to demonstrate a beneficial effect on the rate of joint erosion.